- Home
- WGRX vs TLSI Comparison
WGRX vs TLSI Comparison
Compare WGRX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- TLSI
- Stock Information
- Founded
- WGRX 2022
- TLSI 2010
- Country
- WGRX United States
- TLSI United States
- Employees
- WGRX N/A
- TLSI N/A
- Industry
- WGRX Other Pharmaceuticals
- TLSI Medical Specialities
- Sector
- WGRX Health Care
- TLSI Health Care
- Exchange
- WGRX Nasdaq
- TLSI Nasdaq
- Market Cap
- WGRX 179.7M
- TLSI 160.4M
- IPO Year
- WGRX 2025
- TLSI N/A
- Fundamental
- Price
- WGRX $1.87
- TLSI $5.19
- Analyst Decision
- WGRX
- TLSI Strong Buy
- Analyst Count
- WGRX 0
- TLSI 5
- Target Price
- WGRX N/A
- TLSI $10.90
- AVG Volume (30 Days)
- WGRX 839.1K
- TLSI 41.0K
- Earning Date
- WGRX 05-12-2025
- TLSI 05-15-2025
- Dividend Yield
- WGRX N/A
- TLSI N/A
- EPS Growth
- WGRX N/A
- TLSI N/A
- EPS
- WGRX N/A
- TLSI N/A
- Revenue
- WGRX $28,992,274.00
- TLSI $32,141,000.00
- Revenue This Year
- WGRX N/A
- TLSI $55.13
- Revenue Next Year
- WGRX N/A
- TLSI $50.71
- P/E Ratio
- WGRX N/A
- TLSI N/A
- Revenue Growth
- WGRX N/A
- TLSI 46.20
- 52 Week Low
- WGRX $1.41
- TLSI $3.50
- 52 Week High
- WGRX $7.04
- TLSI $7.55
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- TLSI 45.98
- Support Level
- WGRX N/A
- TLSI $4.96
- Resistance Level
- WGRX N/A
- TLSI $5.68
- Average True Range (ATR)
- WGRX 0.00
- TLSI 0.39
- MACD
- WGRX 0.00
- TLSI -0.00
- Stochastic Oscillator
- WGRX 0.00
- TLSI 37.18
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.